Alphatec Holdings, Inc Q3 2026 Earnings Call - ALPHATEC HOLDINGS INC

Financial Performance:

• Total revenue reached $221 million in Q3 2026, up 13% year-over-year; surgical revenue grew 14% ($202 million), while EOS revenue was $20 million (flat YoY).
• Surgical hardware revenue increased 17%, driven by 25% growth in surgeon adoption and 20% growth in procedure volumes; biologics revenue declined ~$1 million YoY.
• Adjusted EBITDA was $38 million (up 46% YoY) with an expanded margin of 17% (up ~400 bps YoY).
• Gross margin improved to 72% (up ~200 bps YoY) due to inventory efficiency and cost controls, partially offset by lower biologics attachment rates.
• Operating expenses grew 8% YoY but improved 260 bps as a percentage of revenue; free cash flow was positive $6 million for the quarter.
• Balance sheet liquidity totaled $135 million ($80M cash + $55M borrowing capacity); convertible notes repaid using cash on hand.
• Revenue per case declined 5% YoY primarily due to reduced biologics attachment rates.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance lowered to ~$862 million (13% growth), comprising $789M surgical (15% growth) and $73M EOS; implied 17% surgical hardware growth and flat biologics.
• Full-year 2026 adjusted EBITDA guidance reduced to ~$137 million (16% margin) and free cash flow to $10 million.
• Market trends indicate slower thoracolumbar procedure volumes (reflecting broader market softness) offset by strong cervical growth.
• 2027 outlook remains focused on high teens surgical case volume growth, though biologics recovery timing is uncertain; international supply constraints are expected to resolve in 2027.
• EOS capital placements remain "lumpy" due to inconsistent installation dynamics despite healthy underlying demand.

Business Segments and Product Lines:

• Surgical Hardware: Strong growth engine; lateral (PTP) remains a foundational entry point; "Valence" navigation system gaining traction with recent addition of Navigated T-Lift indication.
• Biologics: Identified as a primary drag on growth; company facing "leakage" as competitors target biologics in RFPs while ATEC secures the procedure.
• EOS Imaging: Revenue flat YoY; "EOS Insight" driving deeper clinical workflow integration; EOS Edge installed in >70% of academic institutions with fellowship programs.
• Pediatric/Deformity: Viewed as a long-term opportunity; early adoption of deformity strategies observed in academic centers.
• New Leadership: Tommy Carls appointed EVP of Data Intelligence and Strategy to lead informatics, EOS Edge, and analytics.

Market and Competitive Landscape:

• Orthopedic market growth estimated at mid-single digits to low single digits; ATEC is growing at multiples of the market in cervical and lateral segments.
• Biologics market faces competitive pressure from smaller companies offering lower prices/higher distributor points during hospital RFPs.
• Competitors copying ATEC's lateral (PTP) techniques do not capture the full procedural integration advantage; ATEC retains the "inventor" edge.
• Hospital cost-saving initiatives driving pressure on biologics attachment rates in spine RFPs.

Risks and Challenges:

• Biologics Performance: Significant risk of revenue leakage; sales discipline issues requiring aggressive "carrot and stick" management to secure procedure value.
• Thoracolumbar Softness: Slower volumes in this category reflecting broader market headwinds; expected to persist into Q4.
• International Supply: Temporary supply constraint in international markets (specifically Japan/Australia) due to a sterilization packaging defect; impacted ~$3M in annual sales.
• EOS Capital Adoption: Lumpy installation timelines and inconsistent hospital capital commitment timing creating revenue volatility.

Management Commentary and Tone:

• Tone is frustrated regarding biologics leakage but highly confident in long-term procedural thesis and clinical distinction.
• CEO Pat Miles expressed strong commitment to "owning" the biologics challenge with immediate sales force accountability.
• Management emphasized resilience of the operating model, highlighting that revenue misses have not prevented margin expansion and cash generation.
• CEO described the current quarter as "maddening" regarding biologics but reiterated confidence in the "best days are yet ahead."

Analyst Questions and Answers:

• Biologics Strategy: Clarified that "owning and addressing" involves stricter contract terms, sales team accountability, and ensuring access to hospital RFPs.
• Market Softness: Confirmed slower thoracolumbar volumes are market-wide, not competitive; cervical growth remains robust.
• 2027 Targets: No specific 2027 guidance given yet; expects continued EBITDA drop-through of ~35% on dollar growth, though biologics impact is a variable.
• Valence/Robotics: Management stated they do not track Medtronic vs. internal robot usage for Valence, emphasizing the system's unique "in-field" camera advantage over external competitors.
• Cash Flow: Explained Q4 FCF guidance reduction is due to working capital investments in inventory/instruments to support volume growth, not a change in conversion efficiency.
• International Issue: Highlighted swift, aggressive recall and re-sterilization of affected product packages as evidence of robust quality culture.

Other Key Points:

• ATEC attracted more new surgeons this quarter than ever before, serving as a leading indicator for future adoption.
• The company is investing heavily in "EOS Insight" to convert imaging into a continuously learning data platform, creating a barrier to entry for competitors.
• Revenue guidance implies a ~$12M sequential growth in surgical hardware for Q4, assuming flat biologics.
• The "Procedural Thesis" remains the core strategy: selling complete integrated procedures (Implants + Biologics + Tech) rather than individual products.